Literature DB >> 2459842

Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses.

C Flexner1, S S Broyles, P Earl, S Chakrabarti, B Moss.   

Abstract

Recombinant vaccinia viruses containing either the entire gag/pol gene or the reverse transcriptase (RT) domain of the human immunodeficiency virus (HIV) were constructed. In mammalian cells infected with the recombinant vaccinia virus containing the gag/pol gene, major and minor polypeptides of 55 and 41 kDa were made, but processed gag products (p24/p17/p15) were not detected. In addition, none of the products of the pol open-reading frame were seen. Both the 55- and 41-kDa gag proteins were post-translationally modified by addition of myristic acid residues in recombinant vaccinia-infected cells, and were immunoprecipitated by antiserum to p24 gag, as well as by antisera from HIV-infected patients. These results indicate that neither proteolytic processing nor other HIV proteins are required for myristilation, and suggest that the 55- and 41-kDa gag precursors share the same amino terminus as p17. Cells infected with a separate vaccinia recombinant containing a truncated piece of the gag/pol gene with added start and stop codons at the 5' and 3' ends of the RT reading frame synthesized a major 61-kDa and a minor 51-kDa protein product which reacted immunologically with both a monoclonal antibody to native HIV p66/51 and antisera from HIV-infected patients. These proteins were purified from recombinant vaccinia-infected mammalian cells, and their enzyme activity was found to be similar to that of authentic HIV RT. Cells infected with the vaccinia/RT vector contained approximately 200-fold more RT per milligram of protein than cells infected with HIV. Recombinant RT was inhibited by dideoxynucleoside triphosphates and should be useful in screening for specific inhibitors of this enzyme. Mice inoculated intradermally with 10(8) plaque-forming units of the vaccinia/RT vector developed specific antibodies to the p66/51 proteins of HIV, but anti-HIV antibodies were not detected in mice inoculated with the vaccinia/gag vector.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459842     DOI: 10.1016/0042-6822(88)90504-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

1.  Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

2.  Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses.

Authors:  D Ronen; Y Teitz; N Goldfinger; V Rotter
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

3.  Enzyme activities in four different forms of human immunodeficiency virus 1 pol gene products.

Authors:  Y W Hu; C Y Kang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

4.  Selective infection of human CD4+ cells by simian immunodeficiency virus: productive infection associated with envelope glycoprotein-induced fusion.

Authors:  S Koenig; V M Hirsch; R A Olmsted; D Powell; W Maury; A Rabson; A S Fauci; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

5.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.

Authors:  R R Speck; C Flexner; C J Tian; X F Yu
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  Expression of a processed and a non-processed form of the integrase protein of HIV-1 in the baculovirus system.

Authors:  B Rodner; C Vinga-Martins; N Müller-Lantzsch
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

8.  Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication.

Authors:  H J Prochaska; Y Yeh; P Baron; B Polsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

9.  Lysis of CD4+ lymphocytes by non-HLA-restricted cytotoxic T lymphocytes from HIV-infected individuals.

Authors:  M D Grant; F M Smaill; K L Rosenthal
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

10.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.